Chi KN, et al. - In this double-blind, phase 3 trial involving 525 patients who received apalutamide (an inhibitor of the ligand-binding domain of the androgen receptor) plus androgen-deprivation therapy (ADT) and 527 who received placebo plus ADT, researchers evaluated if adding apalutamide to ADT would extend radiographic progression-free survival and overall survival vs placebo plus ADT among patients with metastatic, castration-sensitive prostate cancer. With apalutamide, overall survival was higher at 24 months vs placebo, as was radiographic progression–free survival. Overall, the authors concluded that castration-sensitive prostate cancer, overall survival and radiographic progression-free survival were significantly longer with the addition of apalutamide to ADT than with placebo plus ADT in these patients. No significant difference in the side-effect profile was observed between the two groups.